Who We Are
Accelerating the day when cancer can be cured
OncoCDx is a non for profit research organization dedicated to advancing precision medicine through innovative diagnostic technologies.
Founded by researchers from renowned international institutions including the University of Cambridge, University of Oxford, and University of California Berkeley. It integrates laboratory discovery and clinical application.
Our work focuses on translating advances in genomics into practical diagnostic tools that empower clinicians and transform outcomes for patients worldwide.
Our Mission
To empower diagnostics with data-driven insights, ensuring every patient has access to personalized and the most effective targeted therapies.
Our Commitment
We believe survival is a fundamental human right.
Through relentless research and innovation we build a future where high-quality, and life-saving healthcare is accessible to everyone.
OncoCDx ® | Encoded in your genes from OncoCDx on Vimeo
Integrate knowledge
with comprehensive Genomic Profiling
for more PERSONALIZED diagnostics
From “One treatment fits all”
For many years, cancer patients have been treated according to standardized protocols that are largely the same for most individuals
These standard protocols are typically based on large clinical trials involving statistically significant numbers of patients. Such studies help determine the proportion of cases in which a treatment is effective and identify the likelihood of potential side effects.¹
¹ Sharma & Sethi, Standard Treatment Guidelines – A Manual for Medical Therapeutics, 6th edition, 2021
To Precision Diagnostics
Personalized medicine is an emerging approach to healthcare that uses an individual’s genetic profile to guide decisions related to the prevention, diagnosis, and treatment of disease.
This approach moves beyond the traditional “ one size fits all” model of diagnostics and therapy, allowing medical decisions to be tailored to the characteristics of each individual patient.
Knowledge of a patient’s genetic profile can help physicians select the most appropriate medication or therapy and determine the optimal dose or treatment regimen.
In many cases, this enables the selection of the right drug, at the right dose, for the right patient, replacing the traditional “ one size fits all” approach to treatment.²
² Gambardella et al., Personalized Medicine: Recent Progress in Cancer Therapy, 2020
Do you need a consultation?
Read more about the OncoCDx a companion diagnostics in cancer immunotherapy
Trusted by leading research institutions
Learn more & review OUR engagement
Human leukocyte antigen (HLA) typing
HLA locus is involved in the mechanisms of tumor tolerance and diagnosis. The HLA class I and class II genotyping along with expression analysis are currently one of the most promising clinical approaches.
Neoantigens prediction and vaccines design
Tumour neoantigens are crucial for immune response to immunotherapy. Identification, scoring and indication neoantigens that induce the strongest immune response, excluding false positives ones is encouraging direction to design personalized cancer vaccines.
Somatic and germline mutations
Reliable identification of somatic and germline mutations is an essential element of cancer genome research and patients' molecular diagnostics.
Multilevel expression analysis
Integration of multiple sequencing technologies leveraged by machine learning technology increases statistical power to detect novel mutations, especially in low purity tumours.
Identification and characterization of functional lncRNAs
Long non-coding RNAs play a crucial role in regulatory biology. They can act as a regulatory factors essential for tumour and microbiome biology. We identify potential lncRNAs and apply machine learning to predict the effects of its mutations.
Molecular Modelling and Computational Biology
Molecular modelling encompasses all methods, theoretical and computational, used to model or mimic the behaviour of molecules. The methods are used in computational biology to study molecular systems ranging from small chemical systems to large biological molecules.
Computer Aided Drug Design (CADD)
Computer-aided drug design includes computational chemistry, molecular modelling, molecular design and rational drug design. Our original in-house tools and knowledge leaded to therapeutic molecules currently being under the last phase of clinical trial.
With a clear conscience, I recommend OncoCDx services. The clients are very satisfied with the analysis performed on raw data generated by Macrogen - in simple as well as in very complex projects.
Remigiusz Arnak, PhD
Central Europe Account Manager
OncoCDx is an innovative and reliable business partner. As a team of experts, they are competent and easily adapt to a rapidly changing environment. A&A Biotechnology is satisfied with the professional service provided by the company and fully recommend the team to work with.
Barbara Pietrzak
Customer service
Contact us
Submit a form and we respond within 24 hours.
Message
send message